ZYME — Zymeworks Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1937653 ·
Last close
$25.26
Market Cap
$1.79B
52W High
$31.34
52W Low
$16.00
ADV30
859,734
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 4,590,000 | — | -42,145,000 | -45,019,000 | 396,964,000 | 179,413,000 | 316,595,000 |
| Mar 2026 | 2,408,000 | — | -47,149,000 | -44,162,000 | 478,215,000 | 244,282,000 | 314,626,000 |
| Dec 2025 | 2,515,000 | — | -44,120,000 | -41,209,000 | 346,527,000 | 41,157,000 | 78,026,000 |
| Sep 2025 | 27,614,000 | — | -22,064,000 | -19,602,000 | 397,269,000 | 64,834,000 | 77,205,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-119,337,000
Investing CF
$92,769,000
Financing CF
$107,573,000
CapEx
$-2,230,000
Dividends Paid
—
Buybacks
$-169,795,000
EPS Diluted TTM
$-2.02
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,171,238,000
Inventory
—
Receivables
$5,930,000
ST Investments
$91,286,000
EBIT TTM
$-149,168,000
Pretax Income TTM
$-151,390,000
Interest Exp TTM
$8,661,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$37,127,000
EBITDA
$-150,652,000
Free Cash Flow
$-65,060,124
Enterprise Value
$1,607,278,464
Total Cash
$270,699,008
Total Debt
$16,007,000
Shares Out
70,959,241
Trailing EPS
$-2.02
Book Value
$1.12
ROE
-72.3%
ROA
-24.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 105,965,000 | -92,535,000 | -81,130,000 | 346,527,000 | 78,026,000 | 268,501,000 | -33,005,000 |
| Dec 2024 | 76,304,000 | -119,817,000 | -122,695,000 | 463,091,000 | 124,323,000 | 338,768,000 | -110,058,000 |
| Dec 2023 | 76,012,000 | -138,007,000 | -118,674,000 | 580,880,000 | 116,074,000 | 464,806,000 | -118,324,000 |
| Dec 2022 | 412,482,000 | 130,486,000 | 124,341,000 | 648,725,000 | 155,769,000 | 492,956,000 | 144,109,000 |
TTM Snapshot
Revenues TTM
$81,263,000
NetIncome TTM
$-102,656,000
OpCashFlow TTM
—
Assets (Latest)
$478,215,000
Forward EPS
$1.17
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GENB | Generate Biomedicines, Inc. | $1.80B | $13.99 | — |
| BHVN | Biohaven Ltd. | $1.80B | $11.93 | — |
| URGN | UroGen Pharma Ltd. | $1.81B | $36.98 | — |
| XNCR | Xencor Inc | $1.82B | $24.50 | — |
| TRVI | Trevi Therapeutics, Inc. | $1.83B | $12.82 | — |
News headlines (Yahoo Finance, 1h cache)
Zymeworks (ZYME) Could Be 39% Undervalued On 2026 Revenue Guidance And CIO Hire
2026-10-09 03:21 · Yahoo
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook
2026-10-02 23:02 · Yahoo
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
2026-09-28 10:00 · Yahoo
Zymeworks Completes Acquisition of Theravance Biopharma
2026-09-23 20:01 · Yahoo
Zymeworks (ZYME), What Is Behind The Renewed Attention?
2026-08-28 19:05 · Yahoo
SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today?
2026-08-26 17:59 · Yahoo
JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy
2026-08-25 16:26 · Yahoo
Zymeworks Shares Rise Ahead of Key FDA Decision on Zanidatamab
2026-08-24 10:48 · Yahoo
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
2026-08-11 13:30 · Yahoo
Zymeworks Announces Participation in Upcoming Investor Conferences
2026-08-11 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.